27.07.2011 • News

Pharmaceutical Product Development Q2 Profit Rises

 

Pharmaceutical Product Development reported second-quarter net income attributable to shareholders of $46.51 million or $0.41 per share, compared to $20.98 million or $0.18 per share in the prior-year period.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.38 per share for the quarter. Analysts' estimate typically excludes one-time items.

Net revenue for the quarter grew 10.2% to $407.70 million from $369.92 million in the second quarter of last year, while11 analysts estimated revenues of $370.79 million for the quarter.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.